Skip to main content

Adverse Drug Reaction

0
Pipeline Programs
8
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Pharmacogenetic Intervention ArmN/A1 trial
Active Trials
NCT02297126Completed4,465Est. May 2019
Genome & Company
Genome & CompanyKorea - Suwon
1 program
Pharmacogenetic Intervention ArmN/A
Helix
HelixCA - San Mateo
1 program
Pharmacogenomic testingN/A
Helix Biopharma
Helix BiopharmaON - Toronto
1 program
Pharmacogenomic testingN/A1 trial
Active Trials
NCT03093818Completed6,950Est. May 2021
Hua Medicine
Hua MedicineChina - Shanghai
1 program
Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World StudyN/A
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World StudyN/A1 trial
Active Trials
NCT01946919Completed18,260Est. Jun 2022
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World StudyN/A
Autonomous Therapeutics
1 program
Post-Marketing Surveillance of the Tanreqing Injection: a Real World StudyN/A1 trial
Active Trials
NCT02094638Completed30,400

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Helix BiopharmaPharmacogenomic testing
Human BioSciencesPharmacogenetic Intervention Arm
Autonomous TherapeuticsPost-Marketing Surveillance of the Tanreqing Injection: a Real World Study
Qilu PharmaceuticalPost-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study

Clinical Trials (4)

Total enrollment: 60,075 patients across 4 trials

NCT03093818Helix BiopharmaPharmacogenomic testing

PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions

Start: Mar 2017Est. completion: May 20216,950 patients
N/ACompleted
NCT02297126Human BioSciencesPharmacogenetic Intervention Arm

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

Start: Mar 2015Est. completion: May 20194,465 patients
N/ACompleted
NCT02094638Autonomous TherapeuticsPost-Marketing Surveillance of the Tanreqing Injection: a Real World Study

Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study

Start: Jan 201430,400 patients
N/ACompleted
NCT01946919Qilu PharmaceuticalPost-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study

Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study

Start: Oct 2012Est. completion: Jun 202218,260 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.